Salute e Benessere
Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along with rising prevalence | DelveInsight
Discover which therapies are expected to grab the major prurigo nodularis treatment market share @
The increasing prevalence of prurigo nodularis, particularly among individuals with underlying skin conditions like atopic dermatitis and eczema, has heightened the demand for effective treatments. The US accounted for approximately diagnosed prevalent cases of prurigo nodularis in 2024. These cases are expected to increase during the forecast period (2025−2034) owing to growing populations, improved diagnostic methods, changes in lifestyle and environmental factors, and advancements in medical technology, allowing for better treatment. Moreover, there is a growing awareness among healthcare professionals and patients about the condition, leading to earlier diagnosis and intervention.
The approval of DUPIXENT (dupilumab) in 2022 and NEMLUVIO (nemolizumab) in 2024 provides a significant breakthrough for patients with moderate-to-severe prurigo nodularis. These prurigo nodularis therapies offer targeted therapies with proven efficacy. As more treatments are developed and approved, expanding access to biologic therapies like DUPIXENT and NEMLUVIO through improved insurance coverage and cost reduction programs could make these therapies more accessible to a broader range of patients.
The emerging prurigo nodularis clinical trial landscape offers a diverse range of therapeutic alternatives, including (Amgen/Kyowa Kirin), (Incyte), (Celldex), and others across various treatment lines. The expected launch of these therapies shall further create a positive impact on the prurigo nodularis market.
The treatment landscape for prurigo nodularis has seen significant advancements in recent years, driven by growing interest from the pharmaceutical sector due to the condition's chronic and distressing nature. Current therapies aim primarily to alleviate itching and inflammation. Potent topical corticosteroids are frequently used to calm inflamed skin and ease itching, while tacrolimus ointment offers a non-steroidal alternative with anti-inflammatory benefits. Moisturizers, or emollients, play a vital role in hydrating dry skin and enhancing the effectiveness of other treatments.
Non-drowsy antihistamines like fexofenadine can also help control the itch. Phototherapy, including UVA or UVB light therapy, is effective in reducing nodules and itching. Psychological support may help patients cope with stress-related flare-ups. In more severe cases, systemic immunosuppressants such as oral corticosteroids, ciclosporin, methotrexate, or azathioprine are prescribed.
A major milestone in treatment was the FDA approval of , the first medication specifically authorized for prurigo nodularis. DUPIXENT, a monoclonal antibody that blocks IL-4 and IL-13 signaling, helps reduce inflammation and severe itching. Another breakthrough came in August 2024 with the FDA approval of , a monoclonal antibody targeting IL-31, offering a new therapeutic option for managing this condition.
To know more about prurigo nodularis treatment guidelines, visit @
Although there are very few approved medications for prurigo nodularis, several drugs are currently under research and development. These include (Amgen/Kyowa Kirin), (Incyte), and (Celldex), which are being investigated as potential treatments for prurigo nodularis.
is an oral JAK1 inhibitor currently in Phase III clinical trials for prurigo nodularis, with data expected by 2026 and a launch anticipated between 2027–2028. In March 2024 , Incyte presented positive late-breaking Phase II data showing that povorcitinib met its primary and secondary endpoints in treating prurigo nodularis. , a topical JAK1/2 inhibitor, is also being investigated for prurigo nodularis, with Phase III trial data was presented in March 2025 , and a launch is anticipated between 2026–2027. Currently, no oral or topical therapies are approved for prurigo nodularis. While the first study, TRuE-PN1, met its primary endpoint and all key secondary endpoints, the second trial, TRuE-PN2, did not reach statistical significance on its primary endpoint despite the numbers favoring OPZELURA.
(formerly AMG 451 / KHK4083) is a monoclonal antibody that targets the OX40 receptor to inhibit and reduce pathogenic T-cells, with potential for treating prurigo nodularis. The company launched a Phase III trial for rocatinlimab in July 2024 to assess its efficacy in treating prurigo nodularis.
The anticipated launch of these emerging therapies is poised to transform the prurigo nodularis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the prurigo nodularis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about prurigo nodularis marketed and pipeline drugs @
Prurigo nodularis is a long-term skin condition marked by the presence of numerous firm, itchy bumps or nodules that often result from persistent scratching or rubbing. These nodules can vary in size and commonly appear on the arms, legs, back, and chest. The main symptom is severe itching, which leads to repeated scratching, worsening the skin lesions, and causing them to become thickened, scaly, or darkened. In more advanced cases, the nodules may break open or become infected due to continuous irritation and trauma.
While the precise cause of prurigo nodularis is not fully understood, it is frequently linked to underlying health issues such as atopic dermatitis, chronic kidney or liver disease, and psychological conditions like anxiety or depression. Diagnosis is mainly clinical, based on the distinct appearance of itchy, raised nodules. Healthcare professionals typically review the patient's medical history, particularly any related conditions, and perform a physical examination to assess the size, number, and distribution of the nodules, which are usually found on the limbs and trunk.
The prurigo nodularis epidemiology section provides insights into the historical and current prurigo nodularis patient pool and forecasted trends for the leading markets. The total diagnosed prevalent cases of prurigo nodularis in the US were around cases in 2024. According to DelveInsight estimates, in 2024, among the age-specific diagnosed prevalent cases of prurigo nodularis in the US, the highest number of cases were found in the =65 years age group, followed by the 25–44 years age group, while the lowest number of cases was observed in the <15 years age group.
The prurigo nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving prurigo nodularis market trends @
report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prurigo nodularis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epidermolysis bullosa companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bullous pemphigoid companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/prurigo-nodularis-market-to-exhibit-growth-at-a-cagr-of-23-2-20202034-driven-by-strong-uptake-of-dupixent-recent-approval-of-nemluvio-promising-jak-and-ox40-inhibitors-in-the-pipeline-along-with-rising-prevalence--delvein-302562650.html